ESLA Stock Analysis: Buy, Sell, or Hold?
ESLA - Estrella Immunopharma, Inc. Common Stock
$0.98
0.03 (3.45%)
▲
5d:
+3.45%
30d:
-14.54%
90d:
-5.5%
BUY
MODERATE Confidence
Analysis Updated: Jun 26, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When ESLA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ESLA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ESLA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ESLA is currently trading at $0.98, which is considered oversold relative to its 30-day fair value range of $0.99 to $1.14.
Technical Outlook: Technically, ESLA is in a uptrend. The price is currently testing key support at $1.02. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: ESLA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $12.00 (+1121.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ESLA is in a uptrend. The price is currently testing key support at $1.02. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: ESLA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $12.00 (+1121.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.99 -
$1.14
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading 1121.0% below Wall St target ($12.00)
Trading Range Analysis
30-Day Trading Range
$0.99 -
$1.14
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.02
Resistance Level
$1.24
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.07
Wall Street Target
$12.00
(+1121.0%)
Share & Embed Analysis
Last updated: June 29, 2026 4:55 AM ET
Data refreshes hourly during market hours. Next update: 5:55 AM
Data refreshes hourly during market hours. Next update: 5:55 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ESLA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 66 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 65 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 65 BUY |
